Walgreens Boots Alliance, Inc. (WBA)
After hours:
| Previous close | 17.53 |
| Open | 17.76 |
| Bid | 17.80 x 3400 |
| Ask | 17.83 x 10200 |
| Day's range | 17.68 - 18.01 |
| 52-week range | 17.25 - 32.89 |
| Volume | |
| Avg. volume | 11,666,272 |
| Market cap | 15.365B |
| Beta (5Y monthly) | 0.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.00 (5.70%) |
| Ex-dividend date | 20 May 2024 |
| 1y target est | N/A |
- Business Wire
Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials
DEERFIELD, Ill. & RIDGEFIELD, Conn., May 02, 2024--Walgreens and Boehringer Ingelheim today announced a strategic collaboration aimed at optimizing recruitment and making clinical trials more accessible, inclusive and equitable. This collaboration will offer people an opportunity to learn about and potentially participate in an important Phase III clinical trial within the familiar and accessible environment of Walgreens pharmacies, reflecting a shared vision to expand access to healthcare and r
- Business Wire
Walgreens Boots Alliance Declares Quarterly Dividend
DEERFIELD, Ill., April 25, 2024--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on June 12, 2024, to stockholders of record as of May 21, 2024.
- Business Wire
Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens Specialty Pharmacy Business
DEERFIELD, Ill., April 25, 2024--Walgreens is expanding its specialty pharmacy services and investing in its capabilities as the company further grows its core pharmacy business to improve patient outcomes and provide greater value to payers and partners. The company today introduced Walgreens Specialty Pharmacy, a holistic offering that expands access to care for patients with complex, chronic conditions and enables partnerships that drive profitability for Walgreens’ pharmacy business. The com
